Abstract
Systemic sclerosis (SSc) is an autoimmune disease characterized by progressive multiorgan fibrosis. While the cause of SSc remains unknown, a perturbed vasculature is considered a critical early step in the pathogenesis. Using fibrinogen as a marker of vascular leakage, we found extensive extravascular fibrinogen deposition in the dermis of both limited and diffuse systemic sclerosis disease, and it was present in both early and late-stage patients. Based on a timed series of excision wounds, retention on the fibrin deposit of the splice variant domain, fibrinogen αEC, indicated a recent event, while fibrin networks lacking the αEC domain were older. Application of this timing tool to SSc revealed considerable heterogeneity in αEC domain distribution providing unique insight into disease activity. Intriguingly, the fibrinogen-αEC domain also accumulated in macrophages. These observations indicate that systemic sclerosis is characterized by ongoing vascular leakage resulting in extensive interstitial fibrin deposition that is either continually replenished and/or there is impaired fibrin clearance. Unresolved fibrin deposition might then incite chronic tissue remodeling.
Competing Interest Statement
JLB has received consulting fees from Jounce Therapeutics, Mestag, Oncurious and Shattuck Labs as well as lab support from Hoffmann La Roche. KA is a co-founder, scientific advisor and board director of Therini Bio. SA has received grants from Boehringer Ingelheim, Janssen and Momenta to his institution and has received personal consultancy fees from AstraZeneca, CSL Behring, Boehringer Ingelheim and TeneoFour.
Footnotes
Conflict of Interest: JLB has received consulting fees from Jounce Therapeutics, Mestag, Oncurious and Shattuck Labs as well as lab support from Hoffmann La Roche. KA is the scientific founder, scientific advisor and director of Therini Bio. SA has received grants from Boehringer Ingelheim, Janssen and Momenta to his institution and has received personal consultancy fees from AstraZeneca, CSL Behring, Boehringer Ingelheim and TeneoFour. AMB received honoraria from Biogen.